Published in J Am Heart Assoc on June 13, 2016
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Neth Heart J (2017) 0.95
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother (2016) 0.80
Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. BMC Cardiovasc Disord (2017) 0.75
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation. Circ Cardiovasc Qual Outcomes (2017) 0.75
Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. Adv Ther (2016) 0.75
Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. PLoS One (2017) 0.75
Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Clin Res Cardiol (2017) 0.75
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med (2015) 8.38
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med (2009) 8.25
A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost (1993) 7.92
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA (1991) 6.05
Validating administrative data in stroke research. Stroke (2002) 5.90
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med (2002) 5.55
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest (2013) 4.71
Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke (2005) 4.07
Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA (2014) 3.59
A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol (2007) 3.56
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation (2014) 3.53
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol (2013) 3.13
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ (2015) 2.83
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med (2011) 2.45
A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf (2012) 2.17
Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace (2014) 2.05
Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res (2005) 1.87
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J (2015) 1.86
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation (2010) 1.68
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood (2014) 1.61
Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood) (2014) 1.52
Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation. Europace (2016) 1.43
Three simple rules to ensure reasonably credible subgroup analyses. BMJ (2015) 1.40
Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost (2015) 1.35
Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study. Pharm Stat (2012) 1.32
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost (2015) 1.31
National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation (2014) 1.19
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc (2013) 1.15
An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf (2011) 1.14
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med (2014) 1.08
Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc (2015) 1.06
Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. Circ Cardiovasc Qual Outcomes (2015) 1.01
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes (2013) 1.00
Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes (2016) 0.96
Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence. Chest (2013) 0.95
Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol (2015) 0.93
International differences in treatment effect: do they really exist and why? Eur Heart J (2013) 0.92
Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: A propensity-matched study of 24,244 patients. Heart Rhythm (2015) 0.92
Consequences for healthcare quality and research of the exclusion of records from the Death Master File. Circ Cardiovasc Qual Outcomes (2013) 0.91
Pharmaceutical Cost-Saving Strategies and their Association with Medication Adherence in a Medicare Supplement Population. J Gen Intern Med (2015) 0.91
Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry. Br J Clin Pharmacol (2014) 0.88
Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation. J Am Heart Assoc (2015) 0.85
Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost (2015) 0.84
Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circ Cardiovasc Qual Outcomes (2015) 0.83
Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost (2015) 0.82
A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center. J Manag Care Spec Pharm (2014) 0.82
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J (2017) 0.81
Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation. Thromb Haemost (2015) 0.79
Data on trial of anticoagulant is to be reanalyzed after discovery that investigators used faulty device. BMJ (2015) 0.76
Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment. JAMA Intern Med (2015) 0.76
Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc (2016) 0.93
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest (2016) 0.75
Observation or inpatient: Impact of patient disposition on outcomes and utilization among emergency department patients with chest pain. Acad Emerg Med (2016) 0.75
Impact of Atrial Fibrillation and Sinus Rhythm Restoration on Reticulated Platelets. Mayo Clin Proc (2015) 0.75